US Edition
News from european-biotechnology.com
If you want to know if European-biotechnology.com is credible or reliable, look no further. We rank European-biotechnology.com as Unknown factuality. Find out more about our methodology here.
Information about European-biotechnology.com
Where is European-biotechnology.com located?European-biotechnology.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top European-biotechnology.com News
PharmaRetatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced.In fact, some of the participants dropped out of the trial because they were losing too much weight, the pharmaceutical company said.Retatrutide is an experimental triple agonist medication, mimicking three different gut hormones in the body GLP-1, G…See the Story
Eli Lilly's Next-Gen Obesity Drug Shows Biggest Weight Loss yet in Clinical Trial
64% Center coverage: 25 sources
Multiple Sclerosis · FranceTolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the disease.See the Story
Sanofi MS Drug Hits Two Setbacks
100% Center coverage: 1 sources
